QuidelOrtho (QDEL) Company Overview

QDEL continues to witness growth on the back of its strong product portfolio.

NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.

QDEL continues to witness growth on the back of its strong product portfolio.

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183 shares of the Company's common stock (“Common Stock”). The Selling Stockholder will rec.

NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, QuidelOrtho insiders caused the company to misrepresent or fail to disclose that (a) QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) excess inventories of COVID-19 tests existed throughout the supply chain; (c) as a result, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the United States; (e) as a result, the company lacked a reasonable basis for positive statements about QuidelOrtho's business, financials, and growth trajectory.

QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.

QuidelOrtho (QDEL) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.90 per share a year ago.

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders.

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part.